![]() |
市場調查報告書
商品編碼
1497759
全球癌症疼痛治療市場:按藥物類型、給藥途徑、應用和最終用途 - 預測(2024-2030)Cancer Pain Management Market by Drug Type (Nerve Blockers, Non-Opioids, Opioids), Route of Administration (Oral, Parental), Application, End-Use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年全球癌痛治療市場規模將達74.2億美元,2024年將達78.6億美元,複合年成長率為6.09%,2030年將達112.3億美元。
癌症疼痛管理是指用於緩解與癌症及其治療相關的疼痛的技術和程序。這種多學科方法是根據患者需求量身定做的,涵蓋多種方法來改善癌症患者的生活品質。用於控制癌症相關疼痛的策略包括藥物治療(例如止痛藥和鴉片類藥物)和非藥物介入(例如物理治療、心理支持和補充療法)。癌症疼痛的有效管理至關重要,因為它直接影響患者的舒適度、功能和整體健康。癌症發病率上升、人口老化、技術進步、監管效率和患者意識的提高正在推動癌症疼痛管理的需求。然而,鴉片類藥物危機、副作用、系統性醫療保健差異、成本障礙以及缺乏全面的疼痛管理知識所帶來的挑戰可能會阻礙市場成長。然而,該領域的新機會在於精準藥物輸送技術、非鴉片類藥物治療的更多採用、綜合數位健康工具以及補充和替代療法的潛力。創新和業務擴張是透過探索非成癮性鎮痛藥、增強的藥物輸送機制、藥物遺傳學和策略聯盟來推動的。
主要市場統計 | |
---|---|
基準年[2023] | 74.2億美元 |
預測年份 [2024] | 78.6億美元 |
預測年份 [2030] | 112.3億美元 |
複合年成長率(%) | 6.09% |
區域洞察
以病人為中心的護理模式和對全面疼痛管理的重視正在美洲創建先進的癌症疼痛管理框架。高醫療保健支出和廣泛的保險覆蓋範圍使得疼痛管理解決方案得到廣泛採用。當地醫療保健系統為癌症患者提供大力支持,包括疼痛管理作為護理的基本方面。由於醫療保健系統不同和國家政策差異,歐盟 (EU) 國家在癌症疼痛管理方法上表現出很大差異。中東和非洲的經濟資源存在顯著的異質性,這直接影響癌痛治療的可用性和品質。亞太地區快速擴張的醫療保健系統已經適應了癌症和相關疼痛日益流行的趨勢。對醫療保健基礎設施和醫生培訓計劃的投資是明顯的回應。強調適當疼痛控制和居家醫療的新政策正在擴大亞太地區癌症疼痛管理解決方案的範圍。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在癌症疼痛管理市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對癌症疼痛管理市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在癌症疼痛管理市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[197 Pages Report] The Cancer Pain Management Market size was estimated at USD 7.42 billion in 2023 and expected to reach USD 7.86 billion in 2024, at a CAGR 6.09% to reach USD 11.23 billion by 2030.
Cancer pain management refers to the practices and procedures employed in alleviating pain associated with cancer and its treatment. This multidisciplinary approach is tailored to the patient's needs and encompasses various methods to improve the quality of life for those with cancer. The strategies used for managing cancer-related pain may include pharmacological treatments, such as analgesics and opioids, and non-pharmacological interventions, such as physical therapy, psychological support, and complementary therapies. Effective management of cancer pain is pivotal because it directly impacts a patient's comfort, functioning, and overall well-being. The rising prevalence of cancer, an aging demographic, technological advancements, regulatory efficiencies, and heightened patient awareness have improved the need for cancer pain management. However, issues arising from the opioid crisis, adverse drug reactions, systemic healthcare disparities, cost barriers, and a lack of comprehensive pain management knowledge may impede market growth. Nevertheless, emerging opportunities within this domain lie in precision drug delivery technologies, increased non-opioid treatment adoption, integrated digital health tools, and the potential of complementary and alternative therapies. Innovation and business expansion are being driven by research into non-addictive analgesics, enhancement of drug delivery mechanisms, pharmacogenetics, and strategic collaborations.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 7.42 billion |
Estimated Year [2024] | USD 7.86 billion |
Forecast Year [2030] | USD 11.23 billion |
CAGR (%) | 6.09% |
Regional Insights
Patient-centric care models and an emphasis on comprehensive pain management have led to an advanced cancer pain management framework in the Americas. High healthcare expenditure, coupled with extensive insurance coverage, allows for significant adoption of pain management solutions. The regional healthcare system provides substantial support for cancer patients, which includes pain management as a fundamental aspect of care. European Union countries exhibit high variability in cancer pain management approaches due to diverse healthcare systems and differing national policies. The Middle East and African region is characterized by significant heterogeneity in economic resources, which directly impacts the availability and quality of cancer pain management. The rapidly expanding healthcare system in the Asia-Pacific region has been adapting to the growing prevalence of cancer and its associated pain. Investment in healthcare infrastructure and physician training programs are evident response measures. New policies emphasizing adequate pain control and home-based care have broadened the scope of cancer pain management solutions in Asia-Pacific.
Market Insights
The market dynamics represent an ever-changing landscape of the Cancer Pain Management Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Pain Management Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Pain Management Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Non-Opioid Painkiller for Mild-to-Moderate Pain
The U.S. Food and Drug Administration (FDA) has given its approval to a new non-opioid medication designed to alleviate mild to moderate pain in cancer patients. This development promises to offer relief without the associated risks of opioid use, such as addiction and overdose. The novel analgesic is poised to become a pivotal component in the pain management regimen, providing a safer alternative for patients and healthcare professionals aiming to mitigate the discomfort caused by cancer while curbing the potential for opioid dependence. [Published On: 2023-10-20]
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
Nevro Corp. announced the introduction of its innovative HFX for PDN solution, signifying a strategic step to tailor its proprietary Senza system to the needs of patients suffering from painful Diabetic Peripheral Neuropathy (PDN). This launch showcases Nevro's commitment to expanding its high-frequency spinal cord stimulation technology for various indications and marks an important milestone in offering more personalized pain treatment options. [Published On: 2023-08-15]
Esteve and Medtronic are Collaborating to Address Cancer Pain Patients' Needs
Esteve, a pharmaceutical company, announced its collaboration with Medtronic, a global pioneer in medical technology, to meet the complex demands of cancer pain patients. This synergistic partnership is focused on delivering innovative solutions to enhance the quality of life for individuals affected by cancer-related pain. Esteve's expertise in pharmaceuticals and Medtronic's advanced medical technology are poised to bring forward a new era in pain management. [Published On: 2022-11-23]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Pain Management Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cancer Pain Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aegis Therapeutics, LLC, Aptinyx Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Glaxosmithkline PLC, Grunenthal Group, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Trevena Inc..
Market Segmentation & Coverage